Potentiation of platelet responsiveness to nitric oxide by angiotensin-(1-7) is associated with suppression of superoxide release

Platelets

Volumn 18, Issue 2, 2007, Pages 158-164

  Rajendran, Sharmalar ^a   Chirkov, Yuliy Y ^a   Horowitz, John D ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Angiotensin (1 7); Nitric oxide; Platelet aggregation; Superoxide

Indexed keywords

ADENOSINE DIPHOSPHATE; ANGIOTENSIN[1-7]; DEXTRO ALANINE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; LUCIGENIN; NITRIC OXIDE; NITROPRUSSIDE SODIUM; SUPEROXIDE;

ADULT; ARTICLE; BLOOD; CELL ISOLATION; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME REPRESSION; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NEUTROPHIL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA;

ANGIOTENSIN I; BLOOD PLATELETS; HUMANS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROPRUSSIDE; PEPTIDE FRAGMENTS; PLATELET AGGREGATION; RECEPTOR, ANGIOTENSIN, TYPE 1; SUPEROXIDES;

EID: 33947096470     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100600936158     Document Type: Article

References (31)

1. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol. 2006;147(Suppl 1):S193-201.
2. Chirkov YY, Holmes AS, Willoughby SR, Stewart S, Wuttke RD, Sage PR, Horowitz JD. Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. J Am Coll Cardiol 2001;37:1851-1857.
3. Chirkov YY, Holmes AS, Chirkova LP, Horowitz JD. Nitrate resistance in platelets from patients with stable angina pectoris. Circulation 1999;100:129-134.
4. Chirkov YY, Holmes AS, Willoughby SR, Stewart S, Horowitz JD. Association of aortic stenosis with platelet hyperaggregability and impaired responsiveness to nitric oxide. Am J Cardiol 2002;90:551-554.
5. Chirkov YY, Holmes AS, Martelli JD, Horowitz JD. Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunction. Am J Cardiol 2004;93:1438-1440.
6. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-1148.
7. Sheppard FR, Kelher MR, Moore EE, McLaughlin NJ, Banerjee A, Silliman CC. Structural organization of the neutrophil NADPH oxidase: Phosphorylation and translocation during priming and activation. J Leukoc Biol. 2005;78:1025-1042.
8. Timmermans PB, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD. Angiotensin II receptors and functional correlates. Am J Hypertens. 1992;5:221S-235S.
9. Ding YA, MacIntyre DE, Kenyon CJ, Semple PF. Angiotensin II effects on platelet function. J Hypertens 1985;3(Suppl 3):S251-S253.
10. Touyz RM, Schiffrin EL. Effects of angiotensin II and endothelin-1 on platelet aggregation and cytosolic pH and free Ca2+ concentrations in essential hypertension. Hypertension 1993;22:853-862.
11. Jagroop IA, Mikhailidis DP. Angiotensin II can induce and potentiate shape change in human platelets: Effect of losartan. J Hum Hypertens 2000;14:581-585.
12. Larsson PT, Schwieler JH, Wallen NH. Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagul Fibrinolysis 2000;11:61-69.
13. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996;27:523-528.
14. Roks AJ, van Geel PP, Pinto YM, Buikema H, Henning RH, de Zeeuw D, van Gilst WH. Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension 1999;34:296-301.
15. Tallant EA, Diz DI, Ferrario CM. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension 1999;34:950-957.
16. Campbell DJ. Bioactive angiotensin peptides other than angiotensin II. In: Epstein M and Brunner HR, editors. Angiotensin II receptor antagonists. Philadelphia: Hanley and Belfus, Inc; 2001;9-27.
17. The HOPE Study Investigators. Effects of an ACE inhibitor, ramipril, on cardiovascular events in high risk patients. New Engl J Med 2000;342:145-153.
18. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041.
19. Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN, Elisaf M; GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens. 2004;18:781-788.
20. Rajendran S, Chirkov YY, Campbell DJ, Horowitz JD. Angiotensin-(1-7) enhances anti-aggregatory effects of the nitric oxide donor sodium nitroprusside. J Cardiovasc Pharmacol 2005;46:459-463.
21. Garcia NH, Garvin JL. Angiotensin-(1-7) has a biphasic effect on fluid absorption in the proximal straight tubule. J Am Soc Nephrol 1994;5:1133-1138.
22. Oliveira MA, Fortes ZB, Santos RA, Kosla MC, De Carvalho MH. Synergistic effect of angiotensin-(1-7) on bradykinin arteriolar dilation in vivo. Peptides 1999;20:1195-1201.
23. Haulica I, Bild W, Mihaila CN, Ionita T, Boisteanu CP, Neagu B. Biphasic effects of angiotensin (1-7) and its interactions with angiotensin II in rat aorta. J Renin Angiotensin Aldosterone Syst 2003;4:124-128.
24. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003;100:8258-8263.
25. Osei SY, Ahima RS, Minkes RK, Weaver JP, Khosla MC, Kadowitz PJ. Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur J Pharmacol 1993;234:35-42.
26. Oudot A, Vergely C, Ecarnot-Laubriet A, Rochette L. Pharmacological concentration of angiotensin-(1-7) activates NADPH oxidase after ischemia-reperfusion in rat heart through AT1 receptor stimulation. Regul Pept. 2005;127:101-110.
27. de Gaetano G, Cerletti C, Evangelista V. Recent advances in platelet-polymorphonuclear leukocyte interaction. Haemostasis 1999;29:41-49.
28. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378-3384.
29. Gawaz M, Reininger A, Neumann FJ. Platelet function and platelet-leukocyte adhesion in symptomatic coronary heart disease. Thrombosis Res 1996;83:341-349.
30. Ott I, Neumann FJ, Gawaz M, Schmitt M, Schomig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 1996;94:1239-1246.
31. Weber C. Platelets and chemokines in atherosclerosis: Partners in crime. Circ Res. 2005;96:612-616.